Zackon discusses a retrospective 20-year analysis, which implies an easier-to-achieve hemoglobin target in myelodysplastic syndrome treatment.
Ira Zackon, MD
Advertisement
Ira Zackon, MD, is the senior medical director of Ontada Medical Office.
Articles by Ira Zackon, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
SimpleScreen CRC Blood Test Meets Endpoints in Clinical Validation Study
2
Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B
3
Eplontersen Misses Primary Endpoint in Phase 3 ATTR-CM Trial
4
Biologic Therapy for Asthma and COPD: Real-World Perspectives From APPs
5